The Icos Alumni: Where Are They Now?

11/18/09Follow @xconomy

(Page 2 of 9)

Mike Bradley, staff scientist, Array Biopharma

Heather Brammer, quality assurance manager, ZymoGenetics

Mike Brandenstein, scientist, Amgen

Jacqueline Brassard, scientific director, pathology, Allergan

Heather (Brand) Brett, scientist, Amgen

Jeff Bridewell, thought leader liaison, Genentech

Doug Burns, principal, DBC Consulting

Katie Carrigan, director of human resources, ZymoGenetics

Jason Carstens, director of process development, CMC Icos

Shannon Carstens, principal product quality leader, Amgen

Allen Casey, group leader, high throughput screening/robotics, Infectious Disease Research Institute

Sommer Castro, research technician, Fred Hutchinson Cancer Research Center

Tina Catterall, managing partner, Global Interactions

Shannon Cavallari, training coordinator, PATH

Shing Chang, R&D director, Drugs for Neglected Diseases Initiative

David Chantry, senior scientist, Genentech

Jay Charleston, owner and principal, STNW Consulting, owner of Stereotome NW

Hao Chen, principal scientist, Calistoga Pharmaceuticals

Janice Chittenden, director of software quality, NeuroVista

Michael Cicirelli, scientist, Theraclone Sciences

Paul Clark, operating partner, Genstar Capital, member of board of directors at Amylin Pharmaceuticals

Courtney Clark, research associate II, Seattle Genetics

Darcey Clark, senior scientist, Amgen [Updated: 12:20 pm Pacific, 3/29/10]

Tony Colasin, consultant, APC Corporate Development & Strategy Consulting

Anita Colvin, technical scientist, CMC Icos

Tom Cox, senior associate scientist, Novo Nordisk

David Crowe, scientist, Mirina

Dee Czaykowski, life sciences consultant [Added 12/30/09]

Jeff Dantzler, senior research associate, Novo Nordisk

Bela Denes, senior director of clinical research and development, Spectrum Pharmaceuticals

Peter de Vries, associate director of translational sciences, Ikaria

Mike Deeley, consultant, Somerset Consulting … Next Page »

Single Page Currently on Page: 1 2 3 4 5 6 7 8 9 previous page

By posting a comment, you agree to our terms and conditions.

  • http://www.northcoastbio.com Johnny T. Stine

    I actually loved our logo – very simple, but it just looked like fun.
    When George R. was recently asked by a reporter from an Everett newspaper about building Icos into a company like Amgen….he replied “…..why would I stop there?”. With a leader like that, like George, one who inspires with energetic goals such as that mentioned – we could’ve done it. We had the tools and the ability to do just that. We had great people who’ve all proven themselves in places before and afterward…….but imagine what we could’ve done behind the hopes of a great leader like George who set that tone….a CEO who knew all of our names, someone who would talk to you like you were a valued asset, a guy that empowered us via ownership. Imagine what we could’ve done…..because that’s all we’re left to do.

    By the way- Luke – I prefer Icosanoids – a play on the word eicosanoid since we were primarily an inflammation company. :-)

  • http://www.xconomy.com/author/ltimmerman/ Luke Timmerman

    Johnny—Unfortunately, I never really got to know George very well because he had already left Icos by the time I started covering the company in 2001. But I made a point of meeting him at his home once a couple years ago when I was based in San Francisco. He wasn’t in great health, but he was still sharp and very much curious about the latest happenings in biotech.

    I haven’t heard the term Icosanoids from eicosanoid, but that made me laugh this morning. It sounds like something from Star Trek. Anybody know if this was also the inspiration for the term “Immunoids” for people who used to work at Immunex?

  • http://www.BiotechStockResearch.com David Miller

    Nice work, Luke. Goes to prove that even though we might lose companies through acquisition we’d really rather keep, it’s not like everything connected with the company disappears. By my eye, the “loss” of Icos created at least a half-dozen new companies and significantly strengthened a dozen or more startups. A nice silver lining.

  • Abby Kliphardt

    Nice article…good to see where my co-workers have ended. I loved my time at ICOS and will always lament the loss of a great company that was a real family….

  • Pingback: The Icos Impact: What to Expect Next Week | Xconomy